Naser Ansari‐Pour

1.9k total citations · 1 hit paper
33 papers, 861 citations indexed

About

Naser Ansari‐Pour is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Naser Ansari‐Pour has authored 33 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Genetics and 6 papers in Hematology. Recurrent topics in Naser Ansari‐Pour's work include Multiple Myeloma Research and Treatments (6 papers), Genetic Associations and Epidemiology (5 papers) and Forensic and Genetic Research (4 papers). Naser Ansari‐Pour is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Genetic Associations and Epidemiology (5 papers) and Forensic and Genetic Research (4 papers). Naser Ansari‐Pour collaborates with scholars based in Iran, United Kingdom and United States. Naser Ansari‐Pour's co-authors include Mohieddin Jafari, Zahra Razaghi‐Moghadam, Neil Bradman, Christopher A. Plaster, Sarah Gooding, Anjan Thakurta, Erin Flynt, Fadi Towfic, Sayed‐Amir Marashi and Paresh Vyas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Naser Ansari‐Pour

31 papers receiving 847 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Why, When and How to Adjust Your P Values?

2019 362 citations Mohieddin Jafari, Naser Ansari‐Pour profile →

Peers

Countries citing papers authored by Naser Ansari‐Pour

Since Specialization

Citations

This map shows the geographic impact of Naser Ansari‐Pour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naser Ansari‐Pour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naser Ansari‐Pour more than expected).

Fields of papers citing papers by Naser Ansari‐Pour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naser Ansari‐Pour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naser Ansari‐Pour. The network helps show where Naser Ansari‐Pour may publish in the future.

Co-authorship network of co-authors of Naser Ansari‐Pour

This figure shows the co-authorship network connecting the top 25 collaborators of Naser Ansari‐Pour. A scholar is included among the top collaborators of Naser Ansari‐Pour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naser Ansari‐Pour. Naser Ansari‐Pour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer RevealsTP53Aneuploidy–driven Metabolic Reprogramming 2023 ·Cancer Research Communications ·Marni B. McClure, Yasunori Kogure, Naser Ansari‐Pour, Yuki Saito, Hann‐Hsiang Chao, Jonathan H. Shepherd, Mariko Tabata, Olufunmilayo I. Olopade, David C. Wedge, Katherine A. Hoadley, Charles M. Perou, Keisuke Kataoka	11
2	The genomic landscape and clonal evolutionary trajectory of classical hairy cell leukemia 2023 ·Leukemia ·(unknown), (unknown), William Tapper, Nicola J. Weston-Bell, David C. Wedge, Naser Ansari‐Pour, Surinder S. Sahota	4
3	Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients 2023 ·Blood ·Gaurav Agarwal, (unknown), (unknown), (unknown), Lisa Ferguson, (unknown), Jaimal Kothari, Naser Ansari‐Pour, Sally Moore, Eileen M. Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding	1
4	Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma 2022 ·Blood ·Naser Ansari‐Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, (unknown), Konstantinos Mavrommatis, Brian A. Walker, Gareth J. Morgan, Nikhil Munshi, Hervé Avet‐Loiseau, Anjan Thakurta	22
5	Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma 2022 ·Blood ·Sarah Gooding, Naser Ansari‐Pour, (unknown), Kübra Karagoz, Ann Polonskaia, (unknown), (unknown), Korsuk Sirinukunwattana, Selina J Chavda, (unknown), Fadi Towfic, Erin Flynt, William E. Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta	13
6	Association of MSY haplotype background with nonobstructive azoospermia is AZF‐dependent: A case‐control study 2021 ·Andrologia ·(unknown), (unknown), (unknown), (unknown), (unknown), Naser Ansari‐Pour	1
7	Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients 2021 ·Blood ·Sarah Gooding, Naser Ansari‐Pour, (unknown), Kübra Karagoz, (unknown), (unknown), (unknown), Fadi Towfic, Erin Flynt, William E. Pierceall, Kwee Yong, Paresh Vyas, Anjan Thakurta	0
8	Target Mutation of CD80 Protein to Enhance Its Binding to CD28 Receptor 2020 ·(unknown), (unknown), Naser Ansari‐Pour	1
9	Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data? 2020 ·The Pharmacogenomics Journal ·C Ingram, Rosemary Ekong, Naser Ansari‐Pour, Neil Bradman, Dallas M. Swallow	3
10	Label-free discrimination of single nucleotide changes in DNA by reflectometric interference Fourier transform spectroscopy 2019 ·Colloids and Surfaces B Biointerfaces ·(unknown), Fereshteh Rahimi, (unknown), Azizollah Shafiekhani, Ali Hossein Rezayan, Naser Ansari‐Pour	7
11	Identification of a missense variant in CLDN2 in obstructive azoospermia 2019 ·Journal of Human Genetics ·Masomeh Askari, Razieh Karamzadeh, Naser Ansari‐Pour, Mohammad Hossein Karimi‐Jafari, Navid Almadani, Mohammad Ali Sadighi Gilani, Hamid Gourabi, Ahmad Vosough, Anahita Mohseni Meybodi, Mehdi Sadeghi, Anu Bashamboo, Ken McElreavey, Mehdi Totonchi	18
12	Genetic legacy of state centralization in the Kuba Kingdom of the Democratic Republic of the Congo 2018 ·Proceedings of the National Academy of Sciences ·Lucy van Dorp, Sara Lowes, Jonathan Weigel, Naser Ansari‐Pour, Saioa López, Javier Mendoza‐Revilla, James A. Robinson, Joseph Henrich, Mark Thomas, Nathan Nunn, Garrett Hellenthal	5
13	Systems genetics of nonsyndromic orofacial clefting provides insights into its complex aetiology 2018 ·European Journal of Human Genetics ·Zahra Razaghi‐Moghadam, (unknown), Saman Farahmand, Naser Ansari‐Pour	4
14	The Genetic Legacy of Zoroastrianism in Iran and India: Insights into Population Structure, Gene Flow, and Selection 2017 ·The American Journal of Human Genetics ·Saioa López, Mark Thomas, Lucy van Dorp, Naser Ansari‐Pour, (unknown), Abigail Jones, (unknown), Lounès Chikhi, Tudor Parfitt, Neil Bradman, Michael E. Weale, Garrett Hellenthal	9
15	A logic-based dynamic modeling approach to explicate the evolution of the central dogma of molecular biology 2017 ·PLoS ONE ·Mohieddin Jafari, Naser Ansari‐Pour, (unknown), Mehdi Mirzaie	11
16	Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4 2016 ·Pharmacogenetics and Genomics ·(unknown), Naser Ansari‐Pour, Rosemary Ekong, Ayele Tarekegn, Christopher A. Plaster, (unknown), Yuval Itan, Endashaw Bekele, Neil Bradman	3
17	Systems Biomedicine of Rabies Delineates the Affected Signaling Pathways 2016 ·Frontiers in Microbiology ·Sadegh Azimzadeh Jamalkandi, Sayed‐Hamidreza Mozhgani, Hamid Gholami Pourbadie, Mehdi Mirzaie, Farshid Noorbakhsh, Behrouz Vaziri, Alireza Gholami, Naser Ansari‐Pour, Mohieddin Jafari	17
18	GTA: a game theoretic approach to identifying cancer subnetwork markers 2015 ·Molecular BioSystems ·Saman Farahmand, (unknown), Naser Ansari‐Pour, Zahra Razaghi‐Moghadam	8
19	Evidence from Y-chromosome analysis for a late exclusively eastern expansion of the Bantu-speaking people 2012 ·European Journal of Human Genetics ·Naser Ansari‐Pour, Christopher A. Plaster, Neil Bradman	25
20	Little genetic differentiation as assessed by uniparental markers in the presence of substantial language variation in peoples of the Cross River region of Nigeria 2010 ·BMC Evolutionary Biology ·Krishna R. Veeramah, Bruce Connell, Naser Ansari‐Pour, Adam Powell, Christopher A. Plaster, David Zeitlyn, Nancy R. Mendell, Michael E. Weale, Neil Bradman, Mark Thomas	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact